May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Lutein and Zeaxanthin and Age–Related Macular Degeneration in the Melbourne Visual Impairment Project
Author Affiliations & Notes
  • H.T. V. Vu
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • L. Robman
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • A. Hodge
    Cancer Council Australia, Melbourne, Australia
  • C. McCarty
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
    Marshfield Clinic Research Foundation, Marshfield, WI
  • H.R. Taylor
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • Footnotes
    Commercial Relationships  H.T.V. Vu, None; L. Robman, None; A. Hodge, None; C. McCarty, None; H.R. Taylor, None.
  • Footnotes
    Support  NHMRC Australia
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3304. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.T. V. Vu, L. Robman, A. Hodge, C. McCarty, H.R. Taylor; Lutein and Zeaxanthin and Age–Related Macular Degeneration in the Melbourne Visual Impairment Project . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3304.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the association of early and/or late age–related macular degeneration (AMD) with dietary intake of lutein/zeaxanthin (LZ) in the population–based sample of the Melbourne Visual Impairment Project. Methods: Permanent residents aged 40 years and older were recruited via a household census using cluster stratified sampling. All available baseline (1992–1994) participants were re–examined in 1997–1999. Follow–up examination included macular stereo photography and extensive food frequency (FFQ) and lifestyle questionnaires. We obtained from the logistic regressions the odds ratios adjusted by age (years), and cigarette smoking duration (>40 years versus ≤40 years) for the daily LZ intake, its squared value, or its quintile indicator with the lowest quintile as the basline category. Results: Of the 2594 participants who attended the follow up examination, 2143 (83%) had a complete record for smoking duration, dietary intake and either clinical or photographic assessment. There were 38 (1.8%) prevalent late cases, and 450 (21%) or 157 (7.3%) prevalent early cases according to the international classification (IC) or Blue Mountains Eye Study (BMES) definitions respectively. The initial analyses found no association of daily LZ intake when examined as a continuous variable or by quintiles, and the lowest odds ratios (95% CI) for those in the second quintiles were 0.80 (0.58–1.12) for any IC AMD, 0.80 (0.57–1.12) for early IC AMD, 0.76 (0.47–1.22) for any BMES AMD, and 0.72 (0.43–1.20) for early BMES AMD. The upward quadratic trends were significant for any or early IC AMD (p = 0.05) with the turning points x0 corresponding to the lowest risk of daily LZ intake in the second quintiles. These trends showed some protective effect for daily LZ intake < x0, and harmful effect for daily LZ intake > x0. When daily LZ intake was adjusted by total energy intake, a higher intake significantly increased the risks of developing any or early AMD in continuous and quintile analyses. The highest odds ratios for those in the top quintiles were 1.44 (1.04–1.98) for any IC AMD, and 1.41 (1.02–1.95) for early IC AMD. The upward quadratic trends were significant for any or early IC AMD (p = 0.01), any BMES AMD (p = 0.04), and early BMES AMD (p = 0.02) with x0’s in the second quintiles. Conclusions: This study showed a possible protective and also a possibly deleterious role of daily intake of LZ. Further studies are clearly needed to elucidate this complex relationship.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×